- Gefitinib and its derivatives of the new method for microwave synthesis
-
The invention discloses a new method for performing microwave synthesis on gefitinib and a derivative thereof. The method comprises the following steps of: at first, synthesizing 6-methoxyl-7-hydroxyl quinazoline-4-one from 2-iodo (bromo)-4-methoxyl-5-hydroxyl cyanophenyl used as an initial raw material and formamidine hydrochloride in a microwave mode; then performing reaction with 4-(3-bromo propyl) morpholine to introduce an alkyl side chain so as to obtain 7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline-4-ketone; in the presence of a catalyst, performing reaction on the obtained product and a chlorination reagent to obtain 4-chloro-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline; finally, performing reaction on 4-chloro-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline and 3-chloro-4-fluoroaniline to obtain a final product 4-(3-chloro-4-fluoroanilino)-7-methoxyl-6-(3-morpholinyl propoxy) quinazoline (gefitinib). The whole route steps are simplified into four steps, the yield is high, the method is convenient to carry out, the dangerousness is low, and the application of high-pollution reagents is reduced; moreover, the whole route is high in economy and suitable for industrial production, and the product cost is reduced. The reaction formula is as shown in the specification.
- -
-
Paragraph 00
(2016/12/22)
-
- Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia
-
A novel series of 4-anilinoquinazoline derivatives (19a-19t) were designed and synthesized through incorporation of the 2-nitroimidazole moiety into the 4-anilinoquinazoline scaffold of EGFR inhibitors. The most promising compound 19h displayed potent EGF
- Cheng, Weiyan,Yuan, Youting,Qiu, Ni,Peng, Peng,Sheng, Rong,Hu, Yongzhou
-
p. 6796 - 6805
(2015/01/08)
-
- THERAPEUTIC COMPOUNDS AND USES THEREOF
-
Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.
- -
-
-
- Facile and efficient oxidation of quinazolines into quinazolin-4(3 H)-ones by peracetic acid
-
A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]
- Jin, Jian-Wen,Zhang, Lin,Meng, Guang-Rong,Zhu, Jian-Hua,Zhang, Qian
-
p. 346 - 351
(2014/01/06)
-
- Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization
-
Based on an (aminoaryl)benzothiazole quinazoline hit structure for kinase inhibition, a systematic optimization program resulted in a lead structure allowing for inhibitory activities in cellular phosphorylation assays in the low nanomolar range.
- Tasler, Stefan,Mueller, Oliver,Wieber, Tanja,Herz, Thomas,Pegoraro, Stefano,Saeb, Wael,Lang, Martin,Krauss, Rolf,Totzke, Frank,Zirrgiebel, Ute,Ehlert, Jan E.,Kubbutat, Michael H.G.,Schaechtele, Christoph
-
supporting information; experimental part
p. 6728 - 6737
(2009/12/09)
-
- Thiazole Analogues and Uses Thereof
-
Compounds of formula (I) and salts and physiologically functional derivatives thereof, wherein R2 is attached at the 4- or 5-position of the thiazole ring and is hydrogen, alkyl, halogen, cyano, alkoxy, haloalkoxy, or alkylamino; X independently represents a divalent linkage group selected from S, O, NR4, SO, or SO2; R4 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or heterocyclyl; R1 is attached at the 4- or 5-position of the thiazole ring and independently represents a group of formula (II): ?wherein the dotted line represents a single or double bond; * indicates the point of attachment to the thiazole ring; and n is 1, 2, or 3. Also disclosed are pharmaceutical compositions comprising the above compounds and method of treatments for cancer and other diseases.
- -
-
-
- 2-arylbenzothiazole analogues and uses thereof
-
The present invention relates to compounds of the general formula (I) and salts, prodrugs, and stereoisomers thereof, wherein Y independently represents S, O, NR2, SO, SO2; A independently represents a fife- or six-membered aromatic carbocycle or heterocycle and wherein R1 to R20 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties.
- -
-
Page/Page column 14
(2008/06/13)
-
- Thiazole analogues and uses thereof
-
The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, R2 is attached at the 4- or 5-position of the thiazole ring and is hydrogen, alkyl, halogen, cyano, alkoxy, haloalkyloxy, or alkylamino; X independently represents a divalent linkage group selected from S, O, NR4, SO, or SO2; R4 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or heterocyclyl; is attached at the 4- or 5-position of the thiazole ring and independently represents one of the following groups of the general formula (II): wherein the dotted line represents a single or double bond; * indicates the point of attachment to the thiazole ring; n is 1,2, or 3.
- -
-
Page/Page column 18
(2008/06/13)
-
- 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
-
The present invention relates to anticancer compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y independently represents S, O, NR 2 , SO, SO 2 ; A independently represents a five- or six-membered aromatic carbocycle or heterocycle and wherein R 1 in formula (I) represents one of the heteroaryl groups defined in the claims.
- -
-
Page/Page column 24
(2010/11/25)
-
- 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
-
The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein the substituent is attached to the 5- or 6- position of the benzazole; Xindependently represents S, O, SO, SO2;Yindependently represents S, O, NR2, SO, SO2;Aindependently represents ←CO-, ←CS-, ←SO-, ←SO2-, ←CO2-, ←CONR8-, ←NR8CO-, ←NR8CONR9-, ←NR8COO-, ←NR8NR9CO-, ←NR8OCO-, ←ONR8CO-, ←NR8SO2-, where ← indicates the point of attachment to R3; and wherein R1 to R19 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties. These compounds are useful as protein kinase inhibitors in the treatment of i.a. cancer.
- -
-
Page/Page column 26
(2008/06/13)
-
- 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
-
The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents -Y are attached to the 5- or 6- position of the benzazole. These compounds are useful as protein kinase inhibitors in the treatment of i.a. cancer.
- -
-
Page/Page column 26
(2008/06/13)
-
- Benzazole analogues and uses thereof
-
The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents —Y are attached to the 5- or 6-position of the benzazole.
- -
-
Page/Page column 17
(2008/06/13)
-
- Benzazole analogues and uses thereof
-
The present invention relates to N2-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.
- -
-
Page/Page column 23
(2008/06/13)
-
- Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core
-
The facile preparation of 4-(3-chloro-4-fluoroanilino)-6-alkoxy-7- aminoquinazolines from their corresponding 7-triflate and 7-fluoro precursors are highlighted.
- Harris, Craig S.,Kettle, Jason G.,Williams, Emma J.
-
p. 7381 - 7384
(2007/10/03)
-
- QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES
-
The present invention relates to compounds of the Formula (I): wherein Z is -NH-, -O- or -S-; R 1 represents bromo or chloro; R 3 represents C 1-3 alkoxy or hydrogen; R 2 is selected from one of the following three groups: (i) Q 1 X 1 - wherein X 1 and Q 1 are as defined herein; (ii) Q 15 W 3 - wherein Q 15 and W 3 are as defined herein; and (iii) Q 21 W 4 C 1-5 alkylX 1 wherein X 1 , W 4 and Q 21 are as defined herein; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm blooded animals; processes for the preparation of such compounds; pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds of formula (I) inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
- -
-
Page/Page column 60
(2010/02/10)
-
- CHEMICAL COMPOUNDS
-
Quinazoline derivatives of formula (I); for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.
- -
-
-
- CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS
-
Quinazoline derivatives of formula (I) (A chemical formula should be inserted here - please see paper copy enclosed herewith) formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in th
- -
-
-
- QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS
-
The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
- -
-
-
- 4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS
-
The invention concerns quinazoline derivatives of Formula (I): wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-6C)alkyl, m is 1, 2 or 3
- -
-
-
- QUINAZOLINE DERIVATIVES
-
The invention concerns quinazoline derivatives of Formula (I ) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-6C)alkyl, m is 1, 2 or 3
- -
-
-
- QUINAZOLINE DERIVATIVES
-
The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group is selected from halogeno, (1-8C)alkyl, (1-6C)alkoxy and any of the other meanings defined in the description, Ra is hydrogen or halogeno, Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy, Rc is hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, and Rd is (1-6C)alkoxy, or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
- -
-
-
- PYRAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS
-
The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3,
- -
-
-